AU652662B2 - Cyclic nitrones - Google Patents

Cyclic nitrones Download PDF

Info

Publication number
AU652662B2
AU652662B2 AU22800/92A AU2280092A AU652662B2 AU 652662 B2 AU652662 B2 AU 652662B2 AU 22800/92 A AU22800/92 A AU 22800/92A AU 2280092 A AU2280092 A AU 2280092A AU 652662 B2 AU652662 B2 AU 652662B2
Authority
AU
Australia
Prior art keywords
compound according
patient
administering
need
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU22800/92A
Other languages
English (en)
Other versions
AU2280092A (en
Inventor
Ronald C. Bernotas
Albert A. Carr
George Ku
Craig E. Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of AU2280092A publication Critical patent/AU2280092A/en
Application granted granted Critical
Publication of AU652662B2 publication Critical patent/AU652662B2/en
Assigned to MERRELL PHARMACEUTICALS INC. reassignment MERRELL PHARMACEUTICALS INC. Request to Amend Deed and Register Assignors: MERRELL DOW PHARMACEUTICALS INC.
Assigned to AVENTIS INC. reassignment AVENTIS INC. Alteration of Name(s) in Register under S187 Assignors: MERRELL PHARMACEUTICALS INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AU22800/92A 1991-09-12 1992-09-08 Cyclic nitrones Ceased AU652662B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75806391A 1991-09-12 1991-09-12
US758063 1991-09-12
US82807592A 1992-01-30 1992-01-30
US828075 1992-01-30

Publications (2)

Publication Number Publication Date
AU2280092A AU2280092A (en) 1993-03-18
AU652662B2 true AU652662B2 (en) 1994-09-01

Family

ID=27116485

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22800/92A Ceased AU652662B2 (en) 1991-09-12 1992-09-08 Cyclic nitrones

Country Status (18)

Country Link
EP (1) EP0532027B1 (OSRAM)
JP (1) JP3255989B2 (OSRAM)
KR (1) KR100232025B1 (OSRAM)
AR (1) AR247731A1 (OSRAM)
AT (1) ATE194599T1 (OSRAM)
AU (1) AU652662B2 (OSRAM)
DE (1) DE69231238T2 (OSRAM)
DK (1) DK0532027T3 (OSRAM)
ES (1) ES2149161T3 (OSRAM)
FI (1) FI101071B (OSRAM)
GR (1) GR3034551T3 (OSRAM)
HU (1) HU216788B (OSRAM)
IL (1) IL103111A (OSRAM)
MX (1) MX9205199A (OSRAM)
NO (1) NO179514C (OSRAM)
NZ (1) NZ244268A (OSRAM)
PT (1) PT532027E (OSRAM)
TW (1) TW257755B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69634647T2 (de) * 1995-09-11 2006-03-02 Aventis Pharmaceuticals Inc. Cyclische Nitrone und pharmazeutische Mittel die sie enthalten
EP1288203B1 (en) * 1995-09-11 2005-04-20 Aventis Pharmaceuticals Inc. Cyclic nitrones and pharmaceutical compositions containing them
DE10303254B3 (de) * 2003-01-28 2004-09-23 Johannes-Gutenberg-Universität Mainz 3,3-Dimethyl-8-oxoisochinoline, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und deren Verwendung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3044930A (en) * 1960-12-08 1962-07-17 Phillips Petroleum Co N-oxides of heterocyclic nitrogen compounds as bird and rodent repellents
EP0496796B1 (en) * 1989-10-17 1994-08-31 Oklahoma Medical Research Foundation Method and compositions for inhibition of disorders associated with oxidative damage

Also Published As

Publication number Publication date
FI924076A0 (fi) 1992-09-11
IL103111A0 (en) 1993-02-21
MX9205199A (es) 1994-01-31
DK0532027T3 (da) 2000-10-23
HU9202923D0 (en) 1992-11-30
NO923538D0 (no) 1992-09-11
JPH05213870A (ja) 1993-08-24
JP3255989B2 (ja) 2002-02-12
PT532027E (pt) 2000-10-31
HUT67022A (en) 1995-01-30
KR100232025B1 (ko) 1999-12-01
ES2149161T3 (es) 2000-11-01
ATE194599T1 (de) 2000-07-15
NO179514B (no) 1996-07-15
DE69231238D1 (de) 2000-08-17
EP0532027B1 (en) 2000-07-12
DE69231238T2 (de) 2000-12-21
AR247731A1 (es) 1995-03-31
EP0532027A1 (en) 1993-03-17
HU216788B (hu) 1999-08-30
NZ244268A (en) 1994-09-27
NO923538L (no) 1993-03-15
FI101071B (fi) 1998-04-15
GR3034551T3 (en) 2001-01-31
AU2280092A (en) 1993-03-18
IL103111A (en) 1996-07-23
NO179514C (no) 1996-10-23
KR930005981A (ko) 1993-04-20
FI924076L (fi) 1993-03-13
TW257755B (OSRAM) 1995-09-21

Similar Documents

Publication Publication Date Title
US5292746A (en) Cyclic nitrones, pharmaceutical compositions thereof and their use in treating shock
US5824699A (en) Carbazole inhibitors of Cox-2
TWI507410B (zh) 新穎磷酸二酯酶抑制劑
JP6162820B2 (ja) 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
SK93994A3 (en) Benzocycloheptenes, benzoxepines and benzothiepines and method their producing
JP3708957B2 (ja) （−）−エゼロリン、（−）−ｎ１−ノルエゼロリンおよび（−）−ｎ１−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩：特異的アセチルコリンエステラーゼ阻害薬としての使用
JP3425424B2 (ja) クロマノンおよびチオクロマノン誘導体
EP0858996A1 (en) Nerve cell protective agents
US11845727B2 (en) Aldehyde and ketone derivatives of psilocybin and methods of using
JPH04234860A (ja) チアジン（又はオキサジン）誘導体、その製法及びその合成中間体
NO851010L (no) Substituerte benzopyraner, fremgangsmaate til deres fremstilling, samt deres anvendelse i legemidler
EP2880023A1 (fr) Derives de griseofulvine
KR100425953B1 (ko) 티오피란유도체
JPH0686434B2 (ja) ベンズアゼピン誘導体
EP0411912A2 (en) Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders
US5025009A (en) Novel benzazepine derivatives
EP0532027A1 (en) Cyclic nitrones, their preparation and pharmaceutical compositions containing them
KR20240036571A (ko) 치료 화합물 및 방법
KR20060061390A (ko) 모노아민 산화효소 비 저해제로서 벤즈아제핀 유도체
US5516795A (en) Heteroatom substituted propanyl derivatives having 5-lipoxygenase inhibitory activity
KR20000029545A (ko) Ｃｏｘ-２에대한피라노인돌및카바졸억제제
PT97570A (pt) Processo para a preparacao de derivados de benzotienopiridina
SK1792000A3 (en) 1,3-DIOXOLO(4,5-H)(2,3)BENZODIAZEPINE DERIVATIVES, PROCESS FORì (54) THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CO
US4868315A (en) Novel aryloxycycloalkanolaminoalkylene aryl ketones
JP2894617B2 (ja) ２―フエニルインドール誘導体

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: MERRELL PHARMACEUTICALS INC.

Free format text: FORMER NAME WAS: MERRELL DOW PHARMACEUTICALS INC.